Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q4 CY2024, with sales up 7.2% year on year to $10.97 ...

We recently published a list of Jim Cramer Breaks Silence On DeepSeek AI Sell-Off & Discusses These 12 Stocks. In this ...

A product made in Columbus reached a major milestone at the end of 2024. Ensure, a nutritional drink made by Abbott ...

This was the stock's fifth consecutive day of gains.

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Abbott Laboratories (NYSE: ABT) Q4 2024 Earnings Call Jan 22, 2025, 9:30 a.m. ET ...

Abbott Laboratories (ABT) reported weaker-than-expected fourth quarter sales due to weakness in its nutrition and diagnostics ...

(Reuters) - Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...

For 2025, Abbott forecast organic sales growth of between 7.5% and 8.5%, as well as adjusted earnings per share of $5.05 to $5.25. Analysts expect $5.16 a share on $42 billion in sales.

In a report released yesterday, David Toung from Argus Research maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The ...